



Press Release

TSXV: ADK

For immediate distribution
Source: DIAGNOS inc.

10.03.26

DIAGNOS announces changes to the Board of Directors and grant of options

Brossard, Quebec, Canada – March 26th, 2010 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, is pleased to announce the appointment of Mr Bruno Maruzzo to the Board of Directors.

He joins the current slate of members: André Larente, Olivier Lerolle, Chris Orchard and Philip Renaud.

Mr Maruzzo has over 20 years experience in working with small to medium size technology companies in the medical and biotechnology fields as well as working in venture capital investing in technology oriented companies. Through his consulting company, TechnoVenture Inc., he has provided general management, financing, business development and technical services to a variety of private and public technology companies. Mr Maruzzo has a unique blend of expertise and experience in seeking funds for technology companies and making investments in technology companies. Being on both sides of a transaction at different times, has given him great insights into company formation, financing and management. He holds a BSc in Electrical Engineering from the University of Waterloo an MASC in Biomedical Engineering and an MBA, both from the University of Toronto.

Following his appointment, the Board of Directors has approved, on March 16th, 2010, a grant of 100,000 stock options, under the terms of the share stock option plan of the Corporation approved by the Shareholders in September 2008.

The exercise price has been established at \$0.38 per share. The expiry date where these options can be exercised has been fixed to March 15th, 2015.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.com